Pulse Biosciences, Inc.

NASDAQ:PLSE

Medical - Instruments & Supplies

Healthcare
$45.83 +3.83%

+$0.97 today

Market cap
$3.37B
Beta
1.66
P/E (TTM)
-24.0
EPS (TTM)
-$1.10
52W Low $12.56High $28.53

Volume 0.33M

Average 0.31M

PLSE Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Pulse Biosciences, Inc.NASDAQ: PLSE

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income growth accelerates

Q2 FY2026 net income of $24.66M (cash outflow) rose 28.6% year over year, ahead of the +17.7% change in trailing-twelve-month net income. Sequentially, it rose 32.7% from the prior quarter. Over 3 fiscal years it compounded at +7.5% a year.

Context

  • Net income amounted to 20794.6% of revenue in FY2025.
  • Net income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 4 analysts of -$73.03M (+0.3%) for the fiscal year ending Dec 2026, a slowdown from the +35.8% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-$24.66M+32.7% QoQ
Last fiscal yearDec 2025
-$72.78M+35.8% YoY
LTMJun 2026
-$80.06M+17.7% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+28.6%+14.8%-13.8 pp
1 year+35.8%+0.3%-35.5 pp
3-year CAGR+7.5%+0.5%-7.1 pp
5-year CAGR-11.6%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(72.78M) USD
Year-over-year change
-35.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How PLSE compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +17.7% is the 8th highest of 11, against a peer median of +68.4%.
  • Net income amounts to 6755.8% of revenue for PLSE, versus a peer median of 116.1%.
PLSE Competitors
Net Income for PLSE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ATAIAtai Beckley Inc.LTM Jun 2026$668.24M USD+459.1%+61.3%14939.4%
IMTXImmatics N.V.LTM Mar 2026€217.14M EUR+906.0%—582.2%
OPKOPKO Health, Inc.LTM Mar 2026$212.92M USD+445.9%-11.8%36.6%
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$192.25M USD+67.5%+78.6%10097.0%
NVCRNovoCure LimitedLTM Mar 2026$173.05M USD+5.4%+13.8%25.7%
NKTRNektar TherapeuticsLTM Jun 2026$157.13M USD+28.5%-23.6%287.8%
KMTSKestra Medical Technologies, Ltd.LTM Jan 2026$143.89M USD+69.3%—171.9%
PLSEPulse Biosciences, Inc.LTM Jun 2026$80.06M USD+17.7%+7.5%6755.8%
BBNXBeta Bionics, Inc.LTM Mar 2026$66.44M USD-6.4%+4.2%60.3%
STAASTAAR Surgical CompanyLTM Apr 2026$21.03M USD-70.4%—7.2%
LFMDLifeMD, Inc.LTM Mar 2026$507.37K USD+105.0%—0.2%
Peer median (excluding PLSE) —+68.4%+9.0%116.1%

Competitors are the stored peer set for PLSE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(63.66M)(58.51M)(42.21M)(53.59M)(72.78M)
Depreciation & Amortization1.15M1.36M1.21M1.18M1.07M
Deferred Income Tax00000
Stock-Based Compensation14.6M5.19M7.18M13.59M21.46M
Change in Working Capital(6.2M)(3.72M)768K2.47M(5.02M)
Accounts Receivables(61K)20K109K48K(274K)
Inventory(5.82M)(2.65M)00(136K)
Accounts Payables1.16M(1.3M)263K(201K)1.13M
Other Working Capital(1.47M)221K396K2.63M(5.74M)
Other Non-Cash Items13K8.66M13K6K1.15M
Operating Cash Flow(54.1M)(47.01M)(33.04M)(36.34M)(54.12M)
Capital Expenditures(437K)(401K)(121K)(125K)(315K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments8M0000
Other Investing Activities0000(20K)
Investing Cash Flow7.56M(401K)(121K)(125K)(335K)
Debt Repayment407K65M000
Common Stock Issued56.7M14.86M16.39M59.65M17.15M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities62.51M75K(6K)50.49M0
Financing Cash Flow62.69M79.94M16.39M110.14M17.15M
Effect of Forex Changes00000
Net Change in Cash16.15M32.53M(16.77M)73.67M(37.3M)
Free Cash Flow(54.53M)(47.41M)(33.16M)(36.47M)(54.44M)

Pulse Biosciences, Inc.

NASDAQ:PLSE

Intrinsic Alpha fair value

Locked

Current Price

$45.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.